Ajovy (Fremanezumab-vfrm)

Ajovy (Fremanezumab-vfrm)

Ajovy

Fremanezumab-vfrm

Injections: 225 mg/1.5 mL 

Teva Pharmaceuticals, Inc.

Medical Use

Ajovy (fremanezumab-vfrm) is a calcitonin gene-related peptide (CGRP) antagonist used for the preventive treatment of migraines in adults.

Recommended Dosage:

  • -Ajovy is administered via subcutaneous injection into areas of the abdomen, thigh, or upper arm that are not bruised, tender, red, or hardened. If multiple injections are needed, they can be given in the same general area but not at the exact same spot as the previous injection.

There are two subcutaneous (SC) dosing options for Ajovy:

  • -225 mg monthly, or
  • -675 mg every three months (quarterly), administered as three consecutive 225 mg SC injections.

When switching dosing options, start the new regimen on the next scheduled administration date. If a dose is missed, administer it as soon as possible, then continue with the regular dosing schedule from the date of the last dose.